- Home
- ATOS vs NBTX Comparison
ATOS vs NBTX Comparison
Compare ATOS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- NBTX
- Stock Information
- Founded
- ATOS 2009
- NBTX 2003
- Country
- ATOS United States
- NBTX France
- Employees
- ATOS N/A
- NBTX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- NBTX Health Care
- Exchange
- ATOS Nasdaq
- NBTX Nasdaq
- Market Cap
- ATOS 174.8M
- NBTX 201.9M
- IPO Year
- ATOS 2012
- NBTX 2020
- Fundamental
- Price
- ATOS $1.54
- NBTX $4.00
- Analyst Decision
- ATOS Strong Buy
- NBTX Strong Buy
- Analyst Count
- ATOS 3
- NBTX 2
- Target Price
- ATOS $6.25
- NBTX $11.50
- AVG Volume (30 Days)
- ATOS 502.2K
- NBTX 6.4K
- Earning Date
- ATOS 11-19-2024
- NBTX 11-19-2024
- Dividend Yield
- ATOS N/A
- NBTX N/A
- EPS Growth
- ATOS N/A
- NBTX N/A
- EPS
- ATOS N/A
- NBTX N/A
- Revenue
- ATOS N/A
- NBTX $45,220,186.00
- Revenue This Year
- ATOS N/A
- NBTX N/A
- Revenue Next Year
- ATOS N/A
- NBTX N/A
- P/E Ratio
- ATOS N/A
- NBTX N/A
- Revenue Growth
- ATOS N/A
- NBTX 526.17
- 52 Week Low
- ATOS $0.62
- NBTX $4.04
- 52 Week High
- ATOS $2.31
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- ATOS 65.98
- NBTX 37.42
- Support Level
- ATOS $1.36
- NBTX $4.07
- Resistance Level
- ATOS $1.66
- NBTX $4.44
- Average True Range (ATR)
- ATOS 0.07
- NBTX 0.21
- MACD
- ATOS 0.02
- NBTX -0.03
- Stochastic Oscillator
- ATOS 80.65
- NBTX 0.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.